ArchiMed
VC Fund
Lyon, France
ArchiMed is an independent group with funds provided by the team as well as European and American investors, both institutional and private (including a number of successful healthcare entrepreneurs).
- Total investments:
- 9
- Last investment:
- Lead investor:
- 44%
- Fund size:
- $761M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries ArchiMed invests in
Stages ArchiMed invests in
Countries ArchiMed invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Investment Focus
Industry
- Health Care 5 (56%)
- Biotechnology 3 (33%)
- Pharmaceutical 3 (33%)
- Manufacturing 2 (22%)
- Medical 1 (11%)
Stage
- Private Equity 4 (44%)
- Funding Round 3 (33%)
- Venture - Series Unknown 1 (11%)
Country
- Italy 2 (22%)
- France 2 (22%)
- Japan 1 (11%)
- Canada 1 (11%)
- Germany 1 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
André-Michel Ballester
Partner
|
Partner | Total investments: 0 | Find email | |
Igor Petricca
Principal
|
Principal | Total investments: 0 | Find email | |
Marcin Goszyk
Principal
|
Principal | Total investments: 0 | Find email | |
Benoit Adelus
Partner
|
Partner | Total investments: 0 | Find email | |
Denis Ribon
Partner & Co-founder
|
Partner & Co-founder | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Agatha
|
Agatha is a provider of strategic software solutions to the health care and life sciences industry. It is dedicated to helping hospitals, biotechnology, pharmaceutical, contract research organizations, and medical device firms optimize the management of their quality and clinical documentation and processes. | Private Equity / Apr 10, 2025 | |
|
Agatha
|
Agatha is a provider of strategic software solutions to the health care and life sciences industry. It is dedicated to helping hospitals, biotechnology, pharmaceutical, contract research organizations, and medical device firms optimize the management of their quality and clinical documentation and processes. | Private Equity / Apr 10, 2025 | |
Ceva Santé Animale
|
Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. FromUganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs. | Private Equity / Mar 31, 2025 | |
PlasmidFactory
|
PlasmidFactory GmbH & Co. KG is a globally active biopharmaceutical company, founded in Bielefeld, Germany, in 2000. The leading contract manufacturing organization (CMO) for plasmid and minicircle DNA has a strong customer base in the fields of cancer research, gene and cell therapy, CAR T-cell development, and vaccination. | Private Equity / Sep 28, 2022 | |
Corealis Pharma
|
Corealis Pharma provides services on a contract basis in the areas of formulation and process development as well as in small-scale clinical trial material manufacturing and the packaging of solid dosage forms to pharmaceutical and biotech companies. Its services include API characterization, salt selection, pre-formulation, formulation and processdevelopment, analytical method development, stability storage, and testing, technical transfer and scale-up, cGMP manufacturing and packaging of phase I and II CTM, and dossier support. | Venture - Series Unknown / May 24, 2022 | |
Clean Cells
|
Clean Cells offers a comprehensive service portfolio ranging from test for viral and biological safety of biopharmaceuticals, the production of cell and virus banks that are GMP grade and secure storage, as well as the production of experimental drugs such as cell therapy products and therapeutic phages. Clean Cells aims to become a major role inthe development of new therapies to revolutionize personalized medicine. | Dec 03, 2018 | |
Centri Dentistici Primo
|
Trust is the basis of every relationship. First knows. Our method of care is based on absolute seriousness and transparency to reach a clear and sincere relationship with the patient. | $5M / Oct 02, 2015 | |
Primo Group
|
Primo Group is the creation of dental clinic chains. In a marketplace where such clinics. | Private Equity / Sep 21, 2015 | |
Citieffe s.r.l.
|
Citieffe s.r.l. develops, manufactures and sells innovative and patented products such as intramedullary nails for trochanter fractures or sophisticated reconstruction-focused external fixation devices. | Jul 01, 2014 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does ArchiMed invest in?
ArchiMed invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Private Equity and Funding Round stage. Most of the 9 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact ArchiMed?
Public channels for ArchiMed include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ArchiMed?
The team at ArchiMed includes André-Michel Ballester (Partner), Igor Petricca (Principal) and Marcin Goszyk (Principal), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
